Complementing Your Psychotherapy

VistaGen Therapeutics CEO Shawn Singh discusses what he and VistaGen are doing to create and improve treatments that complement your practice.

Shawn K. Singh, JD, is the CEO of VistaGen Therapeutics, Inc.

To see more of what VistaGen is doing to improve the medicinal treatments for anxiety and depression, see Benzodiazepines Hit With Boxed Warning by FDA.

Related Videos
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
A new treatment in development is poised to be a game-changer for patients with postpartum depression.
An expert discusses the latest on EndeavorRx and more digital therapeutics for this patient population.
Related Content

The Week in Review: March 27-31

April 1st 2023

Blue Light Blockers: A Behavior Therapy for Mania

October 7th 2021

Gut Microbiota and SSRIs in Major Depression

March 29th 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

Making Connections Between Psychiatry and Dermatology

March 25th 2023

Healing Through Nature

March 23rd 2023

The Week in Review: March 27-31

April 1st 2023

Blue Light Blockers: A Behavior Therapy for Mania

October 7th 2021

Gut Microbiota and SSRIs in Major Depression

March 29th 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

Making Connections Between Psychiatry and Dermatology

March 25th 2023

Healing Through Nature

March 23rd 2023

The Week in Review: March 27-31

April 1st 2023

Blue Light Blockers: A Behavior Therapy for Mania

October 7th 2021

Gut Microbiota and SSRIs in Major Depression

March 29th 2023

Treating ‘Morally Objectionable’ Patients

September 27th 2021

Making Connections Between Psychiatry and Dermatology

March 25th 2023

Healing Through Nature

March 23rd 2023
© 2023 MJH Life Sciences

All rights reserved.